Biosimilars and Patients: Addressing Safety, Cost, Anxiety
Physicians can respond to pushback from patients on switching to a biosimilar by offering resources and discussing options for both biosimilar and reference drugs.
Source: medscape.com
Sameer Awsare News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Sameer Awsare. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Sameer Awsare Today - Breaking & Trending Today
AbbVie's blockbuster drug Humira finally loses its 20-year, $200 billion monopoly
U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.
Source: wbaa.org
Humira loses monopoly as copycat from Amgen comes to market : Shots
U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.
Source: npr.org
AbbVie's blockbuster drug Humira finally loses its 20-year, $200 billion monopoly
U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.
Source: kansaspublicradio.org
AbbVie's blockbuster drug Humira finally loses its 20-year, $200 billion monopoly
U.S. doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited.
Source: kpbs.org